Radiation plus immunotherapy injection for locally advanced pancreatic cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This study tests a new approach for locally advanced pancreatic cancer that hasn't spread. It combines precise high-dose radiation with an experimental immunotherapy (PCX12) injected directly into the tumor to see if it's safe and tolerable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of pancreatic adenocarcinoma, a type of pancreatic cancer.
- After your first chemotherapy, the cancer must still be locally advanced (not spread far) or you chose not to have surgery.
- You must not have had radiation or surgery for this cancer before.
- Your daily activity level should be good (you are up and about more than half the day).
- The tumor must be visible on a CT scan and reachable for a special injection through an endoscope.
- You must be 18 or older and willing to sign a consent form and follow study procedures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of targeted radiation and two oral drugs (defactinib and avutometinib) for people with advanced pancreatic cancer that hasn't spread to distant organs. It may be an option if you've already had at least 2 months of chemo and your cancer is still locally advanced or borderline resectable.
This trial tests a new treatment that uses tiny alpha radiation sources placed directly into the tumor to destroy cancer cells. It is for people with pancreatic cancer that has not spread but cannot be removed surgically, and who have already tried at least one type of chemotherapy or cannot take more chemo.
This trial tests a new combination of an immunotherapy drug (QL1706) and two chemotherapy medicines (AG) as the first treatment for advanced pancreatic cancer. The goal is to see if the combination can shrink tumors and help patients live longer.
This trial tests a combination of radiation, an immunotherapy drug (adebrelimab) and a chemotherapy regimen (NALIRIFOX) before any surgery, for people with locally advanced pancreatic cancer. The goal is to shrink the tumor enough to make surgery possible, potentially improving outcomes.
This trial tests whether combining targeted radiation with an at-home “tumor treating fields” device can better control locally advanced pancreatic cancer. It may help by attacking cancer cells in more than one way after prior chemotherapy.
This trial tests a combination of high-dose radiation (SBRT) and an immunotherapy drug called zimberelimab for people with locally advanced pancreatic cancer that can't be surgically removed. The goal is to see if the combination shrinks tumors or slows their growth better than standard care.
Hear when a new Pancreatic Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.